Clinical Trial Update: Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

This Phase 1 study reports on the combination of celecoxib and erlotinib in patients with stage IIIB or stage IV non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CELEBREX (Celecoxib)
• Tarceva (erlotinib)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Lung Cancer | Phase 1 | Status: COMPLETED